Experimental models of Huntington's disease

被引:9
作者
Garcia-Ramos, R.
del Val-Fernandez, J.
Catalan-Alonso, M. J.
Barcia-Albacar, J. A.
Matias-Guiu, J.
机构
[1] Hosp Clin San Carlos, Unidad Trastornos Movimiento, E-28040 Madrid, Spain
[2] Hosp Clin San Carlos, Serv Neurocirugia, E-28040 Madrid, Spain
[3] Hosp Clin San Carlos, Inst Neurociencias, E-28040 Madrid, Spain
关键词
3-nitropropionic acid; cellular models; excitotoxic models; Huntington's disease; quinolinic acid; Transgenic mice;
D O I
10.33588/rn.4507.2007238
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Huntington's disease (HD) is an autosomal dominant hereditary disease caused by triplet repetition in exon I of the huntingtin protein located in chromosome 4. Medium spiny neurons in the striatum are selectively affected. Clinical manifestations include progressive behavioural, motor and cognitive disorders. There is no treatment available today capable of modifying the natural course of the disease. A great amount of research work is being carried out, much of which involves animal models of the disease. Development. We reviewed the articles published in PubMed on basic research into HD and analysed the most frequently used models. Transgenic mouse models, excitotoxic models, transgenic fly models and cell cultures are all used in studies into HD. The advantages and disadvantages of each of them are highlighted. Conclusion. The contribution made by each model of HD must be known in order to draw up a correct design in experimental studies of the disease. [REV NEUROL 2007; 45: 437-41]
引用
收藏
页码:437 / 441
页数:5
相关论文
共 19 条
[1]   Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease [J].
Blum, D ;
Galas, MC ;
Gall, D ;
Cuvelier, L ;
Schiffmann, SN .
NEUROBIOLOGY OF DISEASE, 2002, 10 (03) :410-426
[2]   Replicating Huntington's disease phenotype in experimental animals [J].
Brouillet, E ;
Condé, F ;
Beal, MF ;
Hantraye, P .
PROGRESS IN NEUROBIOLOGY, 1999, 59 (05) :427-468
[3]   Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease [J].
Canals, JM ;
Pineda, JR ;
Torres-Peraza, JF ;
Bosch, M ;
Martín-Ibañez, R ;
Muñoz, MT ;
Mengod, G ;
Ernfors, P ;
Alberch, J .
JOURNAL OF NEUROSCIENCE, 2004, 24 (35) :7727-7739
[4]   Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice [J].
Chu-LaGraff, Q ;
Kang, XW ;
Messer, A .
BRAIN RESEARCH BULLETIN, 2001, 56 (3-4) :307-312
[5]   Behaviour characterization of a model of Huntington's disease in rats, induced by quinolinic acid [J].
Francis, L ;
Cruz, R ;
Antúnez, I ;
Rosillo, JC .
REVISTA DE NEUROLOGIA, 2000, 30 (11) :1016-1021
[6]   Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid [J].
Guyot, MC ;
Hantraye, P ;
Dolan, R ;
Palfi, SM ;
Maziere, M ;
Brouillet, E .
NEUROSCIENCE, 1997, 79 (01) :45-56
[7]   The use of the R6 transgenic mouse models of Huntington' s disease in attempts to develop novel therapeutic strategies [J].
Li J.Y. ;
Popovic N. ;
Brundin P. .
NeuroRX, 2005, 2 (3) :447-464
[8]   Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila [J].
Liévens, JC ;
Rival, T ;
Iché, M ;
Chneiweiss, H ;
Birman, S .
HUMAN MOLECULAR GENETICS, 2005, 14 (05) :713-724
[9]   A cellular model that recapitulates major pathogenic steps of Huntington's disease [J].
Lunkes, A ;
Mandel, JL .
HUMAN MOLECULAR GENETICS, 1998, 7 (09) :1355-1361
[10]   Fly models of Huntington's disease [J].
Marsh, JL ;
Pallos, J ;
Thompson, LM .
HUMAN MOLECULAR GENETICS, 2003, 12 :R187-R193